 Four abstracts regarding zenocutuzumab Zeno, including results from an independent epidemiology study of the prevalence of NRG1 gene fusion-positive NRG1 cancers, will be presented at the American Society for Clinical Oncology ASCO20 Virtual Scientific Program ASCO, May 29-31, 2020. Abstracts detailing interim data from the Phase 1 MCLA-117 acute myeloid leukemia AML trial and an analysis of an extensive, proprietary panel of CD3 bispecific antibodies will be presented at the 25th European Hematology Association EHA Annual Congress Virtual Edition, June 11-14, 2020. 